CLDX Celldex Therapeutics Inc.

-0.17  -4%
Previous Close 3.96
Open 3.96
Price To Book 0.38
Market Cap 47146577
Shares 12,439,730
Volume 408,676
Short Ratio
Av. Daily Volume 518,835

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 2019.
Recurrent/metastatic head and neck squamous cell cancer
Phase 1/2 data presented November 17, 2018 at the Society for Neuro-oncology (SNO) Meeting.
Varlilumab and nivolumab
Solid tumors - cancer
Trial discontinued early March 2016 as unlikely to meet primary endpoint
CDX-110 rindopepimut - ACT IV
Cancer- glioblastoma multiforme (GBM) front line
Phase 2b data released April 16, 2018 - primary endpoint not met.
Glembatumumab vedotin
Metastatic triple negative breast cancers that overexpress gpNMB
Phase 2 presentation at AACR April 15, 2018.
Non-small Cell Lung Cancer (NSCLC)
Phase 1 updated data at AACR April 1, 2019.
Solid tumors

Latest News

  1. Celldex (CLDX) Down 5.7% Since Last Earnings Report: Can It Rebound?
  2. Celldex Presents Positive Interim Results from Phase 1 Study of CD40 Agonist CDX-1140 at American Association for Cancer Research (AACR) Annual Meeting 2019
  3. Celldex Presents Promising Data from CDX-527 Bispecific and TAM Receptor Programs at American Association for Cancer Research (AACR) Annual Meeting 2019
  4. Is Celldex Therapeutics (CLDX) Stock Outpacing Its Medical Peers This Year?
  5. Edited Transcript of CLDX earnings conference call or presentation 7-Mar-19 9:30pm GMT
  6. Celldex (CLDX) Q4 Loss Narrower than Expected, Sales Beat
  7. Celldex Therapeutics' Cost-Cutting and Reverse Stock Split Help Keep It Rolling
  8. Celldex Therapeutics, Inc (CLDX) Q4 2018 Earnings Conference Call Transcript
  9. Celldex Provides Corporate Update and Reports Full Year 2018 Results
  10. Daily Biotech Pulse: Allergan's Depression Drug Flunks Late-Stage Trial, Apellis Offering, ShockWave Medical IPO
  11. Celldex Therapeutics (CLDX) Stock Sinks As Market Gains: What You Should Know
  12. Analysis: Positioning to Benefit within Applied Materials, MRC Global, Meritor, Celldex Therapeutics, Quaker Chemical, and Cubic — Research Highlights Growth, Revenue, and Consolidated Results
  13. The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna
  14. 5 Tiny Biotech Stocks With Superb Growth Potential
  15. The Celldex Reverse Stock Split: What Investors Need To Know
  16. Biotech Stocks To Watch
  17. Celldex Therapeutics Announces Reverse Stock Split
  18. 4 Healthcare Stocks The Market is Watching on Tuesday (2/5/19)
  19. Biotech Stocks to Watch
  20. These 4 Tech Stocks Could Set February Highs